Clinical Trials Browser

Nasopharyngeal Carcinoma × Lymphoid × Clear all

Nasopharyngeal Carcinoma, Carcinoma, Renal Cell, Lymphoma, Non-Hodgkin

NCT02287311 2025-02-24

MABEL

Phase 1 Active not recruiting

38 enrolled 16 charts

Head & NeckLymphoid

Nasopharyngeal Carcinoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Smooth Muscle Tumor

NCT03674567 2025-01-24

Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab

Phase 1/2 Completed

323 enrolled

BreastGenitourinaryGynecologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Lymphoma

NCT02822495 2023-06-15

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

No longer available

Head & NeckLymphoidSarcoma

Nasopharyngeal Carcinoma, Primary Immunodeficiency Diseases, Arthritis, Rheumatoid, Infections, Leiomyosarcoma, Lymphoma, Lymphoproliferative Disorders, Inflammatory Bowel Diseases, Lymphoma, AIDS-Related, Epstein-Barr Virus Infections

NCT05415098 2022-11-16

Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

Phase 1 Unknown

90 enrolled

GastrointestinalHead & NeckLymphoidOther solid neoplasmSarcomaThoracic

Nasopharyngeal Carcinoma, Lymphoma, Non-Hodgkin, Mesothelioma, Sarcoma, Stomach Neoplasms, Lymphoma, B-Cell

NCT01447056 2020-02-07

MALTED

Phase 1 Completed

37 enrolled

Head & NeckLymphoidSarcoma

Nasopharyngeal Carcinoma, Hodgkin Disease, Leiomyosarcoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders

NCT03044743 2017-05-02

PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies

Phase 1/2 Unknown

20 enrolled

GastrointestinalHead & NeckLymphoid

Nasopharyngeal Carcinoma, Hodgkin Disease, Stomach Neoplasms, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

Clinical Trials

Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)